Feedback

Dermal open flow microperfusion for PK-based clinical bioequivalence studies of topical drug products

Affiliation
HEALTH—Institute for Biomedicine and Health Sciences ,JOANNEUM RESEARCH Forschungsgesellschaft mbH ,Graz ,Austria
Birngruber, Thomas;
Affiliation
HEALTH—Institute for Biomedicine and Health Sciences ,JOANNEUM RESEARCH Forschungsgesellschaft mbH ,Graz ,Austria
Tiffner, Katrin I.;
Affiliation
HEALTH—Institute for Biomedicine and Health Sciences ,JOANNEUM RESEARCH Forschungsgesellschaft mbH ,Graz ,Austria
Mautner, Selma I.;
Affiliation
HEALTH—Institute for Biomedicine and Health Sciences ,JOANNEUM RESEARCH Forschungsgesellschaft mbH ,Graz ,Austria
Sinner, Frank M.

Topically applied drug products have experienced an extraordinary price increase in the United States, mostly due to a lack of generic products. Generic drug development is hindered by high costs and risks associated with clinical endpoint studies required to show bioequivalence (BE) of prospective generic products relative to their reference products. There is a continued need for cost- and time-efficient alternatives to clinical endpoint studies to determine BE of topically applied dermal drug products. Cutaneous PK-based BE studies present such an alternative and dOFM (dermal open flow microperfusion) has already been successfully used in several verifications studies to show an accurate and sensitive assessment of the rate and extent at which drugs become available in the skin. dOFM technology is discussed as well as the dOFM setup of clinical pilot and main studies to achieve BE assessment with a minimum number of participants and an outlook is given on the use of dOFM technology for other drug products.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Birngruber, Tiffner, Mautner and Sinner.

Use and reproduction: